News
AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases
CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding patterns of target proteins with existing compound molecules in order to identify those with the highest chance of success in clinical trials, according to the release.
Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...
For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million verdict ...
An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...
Understand every aspect of the global economy – and know how to make your next move.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
VOV.VN - Prime Minister Pham Minh Chinh has proposed that AstraZeneca consider building a pharmaceutical manufacturing plant ...
Sanjeev Kumar Panchal has stepped down as Managing Director of AstraZeneca Group. The company has appointed Praveen Rao ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback